Diurnal Group PLC (LON:DNL) insider John Goddard bought 10,791 shares of Diurnal Group stock in a transaction that occurred on Friday, January 5th. The stock was purchased at an average price of GBX 540 ($7.22) per share, with a total value of £58,271.40 ($77,913.36).
Diurnal Group PLC (DNL) opened at GBX 164.50 ($2.20) on Friday. The firm has a market capitalization of $105.42 and a PE ratio of -913.89. Diurnal Group PLC has a 52 week low of GBX 105 ($1.40) and a 52 week high of GBX 165 ($2.21).
Separately, Numis Securities reiterated a “buy” rating and set a GBX 185 ($2.47) price objective on shares of Diurnal Group in a research note on Monday, December 18th.
TRADEMARK VIOLATION WARNING: This news story was published by Equities Focus and is owned by of Equities Focus. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.equitiesfocus.com/2018/01/07/diurnal-group-plc-dnl-insider-john-goddard-buys-10791-shares.html.
Diurnal Group Company Profile
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.
Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.